DOI: 10.1055/s-00033990

TH Open

LinksSchließen

Referenz

Novo Nordisk.
FDA Approves NOVO NORDISK's NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients with Inhibitors.
Available at:
http://press.novonordisk-us.com/News-Releases?item=122388

Bibliographische Angaben herunterladen

Suchen in: